Free tool
FAERS Monitor: Nexiclon Xr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022500 or its brand name (Nexiclon Xr, Clonidine). Reports on generic versions are filed under their own applications.
Reports
51,063
Serious
35,861
70% of reports
Hospitalization
18,436
Death reported
6,117
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,905
- pain3,144
- nausea3,068
- fatigue3,049
- off label use3,046
- headache2,949
- hypertension2,704
- dyspnoea2,376
- diarrhoea2,359
- vomiting2,146
- chronic kidney disease2,116
- dizziness1,934
- renal failure1,920
- acute kidney injury1,861
- blood pressure increased1,684
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 509 |
| 2005 | 983 |
| 2006 | 964 |
| 2007 | 945 |
| 2008 | 929 |
| 2009 | 1,298 |
| 2010 | 1,558 |
| 2011 | 1,792 |
| 2012 | 1,951 |
| 2013 | 1,768 |
| 2014 | 2,447 |
| 2015 | 2,894 |
| 2016 | 3,175 |
| 2017 | 3,151 |
| 2018 | 3,590 |
| 2019 | 3,735 |
| 2020 | 3,082 |
| 2021 | 2,798 |
| 2022 | 2,534 |
| 2023 | 2,813 |
| 2024 | 2,943 |
| 2025 | 2,899 |
| 2026 | 2,305 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,003,096 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 2,116 | 11.8 | 11.3 | 20,337 |
| renal failureSignal | 1,920 | 6.0 | 5.8 | 7,981 |
| hypertensionSignal | 2,704 | 5.3 | 5.1 | 9,440 |
| acute kidney injurySignal | 1,861 | 5.1 | 4.8 | 6,026 |
| blood pressure increasedSignal | 1,684 | 4.6 | 4.4 | 4,685 |
| painSignal | 3,144 | 2.1 | 2.0 | 1,890 |
| headache | 2,949 | 1.9 | 1.9 | 1,381 |
| vomiting | 2,146 | 1.9 | 1.8 | 906 |
| dyspnoea | 2,376 | 1.7 | 1.7 | 751 |
| fatigue | 3,049 | 1.6 | 1.6 | 739 |
| dizziness | 1,934 | 1.6 | 1.5 | 443 |
| nausea | 3,068 | 1.6 | 1.5 | 712 |
| diarrhoea | 2,359 | 1.5 | 1.4 | 413 |
| off label use | 3,046 | 1.4 | 1.4 | 416 |
| drug ineffective | 3,905 | 1.2 | 1.2 | 166 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.